Summary:
Summary Statement of Deficiencies D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on a routine desk review of the CMS-155 report for Proficiency Testing (PT) performance and email communications with the laboratory owner, the laboratory failed to achieve satisfactory performance scores for the American Proficiency Institute (API) PT for Cell I.D or WBC Diff testing for two out of three PT events, (event 3 in 2021 and event 1 in 2022). See D2130. D2130 HEMATOLOGY CFR(s): 493.851(f) Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on a routine desk review of the CMS-155 report for Proficiency Testing (PT) performance and email communications with the laboratory owner, the laboratory failed to achieve a score of 80% for the American Proficiency Institute (API) PT for Cell I.D. or WBC Diff for event 3 in 2021 and event 1 in 2022. Findings: 1. A review of the CMS-155 Individual Laboratory Profile on 10/11/2022, at 12:00 pm, revealed the API PT for Cell I.D. or WBC Diff testing scores for event 3 in 2021 was 0% and for event 1 in 2022 was 67%. 2. Email received from the laboratory owner on 10/11 /2022, at 03:07 pm, confirmed two consective unsuccessful PT scores for Cell I.D. or WBC Diff testing due to clerical errors. -- 2 of 2 --